Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    CAR-TCR Global 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Immuno-Oncology

miCAR: combining microRNA gene silencing with CAR expression 4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
Developing CAR T-cell therapy for HIV 4:37
Developing CAR T-cell therapy for HIV
Marco Alessandrini • 20 May 2021
Hypoimmunogenic iPSCs: avoiding immune rejection 5:05
Hypoimmunogenic iPSCs: avoiding immune rejection
Sonja Schrepfer • 27 May 2021
DARIC33 CAR T-cells in AML 2:38
DARIC33 CAR T-cells in AML
Jacob Appelbaum • 12 May 2021
Advances in cell-based therapies for MS 4:55
Advances in cell-based therapies for MS
Jakob Dupont • 17 Jun 2021
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Advances in CAR T-cell expansion technology 11:41
Advances in CAR T-cell expansion technology
Lei Yu • 3 Jun 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS 1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
SURPASS: evaluating the next-generation of SPEAR T-cell therapy 1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
Off-the-shelf iPSC therapies for solid tumors 4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
Innovations within the CAR T-cell field 1:40
Innovations within the CAR T-cell field
Hong Ma • 19 Feb 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy